Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Invested Capital (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Invested Capital for 14 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 142.59% year-over-year to $14.3 million, compared with a TTM value of $14.3 million through Dec 2025, up 142.59%, and an annual FY2025 reading of $14.3 million, up 142.59% over the prior year.
  • Invested Capital was $14.3 million for Q4 2025 at Heron Therapeutics, down from $14.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $196.2 million in Q1 2021 and bottomed at -$40.0 million in Q3 2024.
  • Average Invested Capital over 5 years is $15.3 million, with a median of -$16.6 million recorded in 2022.
  • The sharpest move saw Invested Capital crashed 350.32% in 2023, then surged 142.59% in 2025.
  • Year by year, Invested Capital stood at $77.6 million in 2021, then tumbled by 82.5% to $13.6 million in 2022, then crashed by 350.32% to -$34.0 million in 2023, then grew by 0.95% to -$33.7 million in 2024, then surged by 142.59% to $14.3 million in 2025.
  • Business Quant data shows Invested Capital for HRTX at $14.3 million in Q4 2025, $14.9 million in Q3 2025, and -$27.3 million in Q2 2025.